Abstract

BACKGROUNDS AND OBJECTIVES: This investigation described clinicopathological features and outcomes of extraskeletal myxoid chondrosarcoma (EMC) patients.METHODS: EMC patients were identified from the United States Sarcoma Collaborative database between 2000 and 2016. Overall survival (OS) and recurrence-free survival (RFS) were calculated, and prognostic factors were analyzed.RESULTS: Sixty individuals with a mean age of 55 years were included, and 65.0% (n=39) were male. 73.3% (n=44) had a primary tumor. A total of 41.6% (n=25) developed tumor relapse following resection. The locoregional recurrence rate was 30.0% (n=18/60), and mean follow-up was 42.7 months. The 5-year OS was 71.0%, while the 5-year RFS was 41.4%. On multivariate analysis for all EMC, chemotherapy (hazard ratio[HR], 6.054; 95% confidence interval [CI], 1.33-27.7; p=0.020) and radiation (HR, 5.07, 95% CI, 1.3-20.1; p=0.021) were independently predictive of a worse RFS. Among patients with primary EMC only, the 5-year OS was 85.3%, with a 30.0% (n=12) locoregional recurrence rate, though no significant prognostic factors were identified.CONCLUSIONS: Long-term survival with EMC is probable, however there exists a high incidence of locoregional recurrence. While chemotherapy and radiation were associated with a worse RFS, these findings were likely confounded by recurrent disease as significance was lost in the primary EMC-only subset.

View details for DOI 10.1002/jso.27062

View details for PubMedID 35962783